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ABSTRACT 
 
The fact that insulin and thyroid hormones influence 
each other actions assumes significance since diabetes 
mellitus and thyroid disease are the two common 
endocrine disorders in adult population. Poorly 
controlled diabetes results in a low T3 state and a loss 
of TSH response to TRH.  Regardless of glycemic 
control there is an absence of nocturnal THS peak. 
There is an increased incidence of dysthyroid optic 
neuropathy in patients with Graves disease and co-
existent diabetes.  Also, the visual prognosis after 
treatment is poor.  50% of thyrotoxic patients who were 
previously euglycemic exhibit variable glucose 
intolerance while frank diabetes occurs in 2-3% cases.  
In diabetic patients presence of thyrotoxicosis 
deteriorates the glycemic control. 
 
Diabetic patients with hypothyroidism may suffer from 
recurrent episodes of hypoglycemia. Type 1 diabetes 
mellitus patients have a high prevalence of thyroid 
dysfunction with nearly one third of all newly detected 
patients showing thyroid autoimmunity.  Also, Type 1 
diabetes mellitus and hypothyroidism co-exist in downs 
syndrome as well as congenital rubella. In autoimmune 
polyglandular syndrome Type 2, autoimmune thyroid 
disease and immune mediated diabetes are among the 
components.  
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INTRODUCTION 
 
Diabetes mellitus and thyroid diseases are the two 
common endocriniopathies seen in the adult population.  
With insulin and thyroid hormones being intimately 
involved in cellular metabolism and thus excess or 
deficit of either of these hormones could result in the 
functional derangement of the other.  This article will 
review how diabetes affects thyroid function in 
euthyroid individuals, how it affects pre-existing 
thyroid disorders, conversely how thyroid diseases 
could affect the glycemic status and finally discuss 
clinical situations where both the diseases could co-
exist. 
 
EFFECT OF DIABETES ON THYROID 
FUNCTION 
 
In euthyroid individuals with diabetes mellitus, the 
serum T3 levels, basal TSH levels and TSH response to 
thyrotropin releasing hormone (TRH) may all be 
strongly influenced by the glycemic status (1).  Poorly 
controlled diabetes, both Type 1 and Type 2, may 
induce a “Low T3 state” characterized by low serum 
total and free T3 levels, increase in reverse T3 (rT3) but 
near normal serum T4 and TSH concentrations (2). 
Low serum T3 is due to reduced peripheral conversion 
of thyroxine (T4) to tri-iodothyronine (T3) via 5’ 
monodeiodination reaction. Studies indicate that it may 
be the long term diabetic control that determines the 
plasma T3 levels (1). Poorly controlled diabetes may 
also result in impaired TSH response to TRH or loss of 
normal nocturnal TSH peak. TSH responses and “low 
T3 state” may normalize with improvement in glycemic 
status but even with good diabetes control, the normal 
nocturnal TSH peak may not be restored in C-peptide 
negative patients i.e. those with totally absent 
pancreatic beta cell function  (3). 
 
EFFECT OF DIABETES MELLITUS ON 
THYROID DISEASES (GRAVES 
ORBITOPATHY) 
 
Dysthyroid optic neuropathy (DON) resulting in 
blindness is the most threatening complication of 
Graves’ orbitopathy (GO). It is caused due to the 
compression of optic nerve by enlarged extraocular 
muscles at the orbital apex. Incidence of DON in 
patients with diabetes mellitus is higher than that seen 
in control “GO” group with some studies showing 10 
fold rise in prevalence in diabetic patients.  The higher 
prevalence has been explained by reduced oxygenation 
of optic nerve in diabetic patient owing to the 
vasculopathy making it more susceptible to the pressure 
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effect.  Also it has been documented that the visual 
recovery after treatment in patients with DM and DON 
may not be as good as in non-diabetic patients (4). 
 
EFFECT OF HYPERTHYROIDISM ON 
GLYCEMIC STATUS 
 
Graves disease is the commonest cause of 
hyperthyroidism. While Graves disease may be 
associated with type 1 diabetes in polyglandular 
autoimmune syndrome, thyrotoxicosis by itself is 
diabetogenic.  Variable glucose intolerance is seen in 
up to 50% of patients with graves and frank diabetes 
occurs in 2-3%, when hyperthyroidism develops in 
normal individuals. In known diabetic patients, the 
diabetic control deteriorates (2). Varied metabolic 
changes may occur as a result of hyperthyroidism and 
contribute to the deterioration of glycemic control 
status and these changes are outlined below. 
 
1. Gastrointestinal System 
 
In hyperthyroidism, there is accelerated gastric 
emptying, enhanced intestinal glucose absorption and 
an increase in portal venous blood flow (4).  
 
2. Insulin Secretion  
 
While some studies show decreased insulin secretion in 
hyperthyroidism (5, 6) most of the studies report either 
normal or increased levels of insulin in the peripheral 
and portal circulation (7).  It is possible that there could 
be a masking of increase in insulin secretion due to 
increased degradation of insulin.  In hyperthyroidism, 
the insulin clearance rate is reported to be increased by 
about 40% (8). Long term thyrotoxicosis has been 
shown to cause beta cell dysfunction resulting in 
reduced pancreatic insulin content, poor insulin 
response to glucose and decreased rate of insulin 
secretion (9). 
 
3. Endogenous Glucose Production 
 
In hyperthyroidism the endogenous glucose production 
is greatly increased by a variety of mechanisms: (a) 
there is an increase in the availability of gluconeogenic 
precursors in the form of lactate, glutamine and alanine 
from skeletal muscles and glycerol from adipose tissue, 
(b) there is an increase in the concentration of plasma 
FFA stimulating hepatic gluconeogenesis (10); (c) there 
is an increase in glycogenolysis due to inhibition of 
glycogen synthesis resulting in hepatic glucose output 
even in fed state (11); (d) there is an upregulation of 
GLUT-2 glucose transporters protein expression in the 
hepatocyte plasma membrane. This permits increased 
glucose efflux to occur without intracellular glucose 
accumulation which would limit hepatic glucose 
production (12); (e) finally,   there is increased 
secretion and exaggerated effects of glucagon and 
adrenaline on liver cells (10). 
 
4. Glucose Utilization  
 
Adipose Tissue 
 
In adipocytes isolated from rats or hyperthyroid 
patients, the sensitivity of glucose transport and 
utilization to insulin has been found to be normal, 
increased or decreased. The varied results probably 
reflect to regional differences in the metabolic 
characteristics of isolated adipocytes (5.10). 
 
Skeletal Muscle 
 
In skeletal muscle, there is a preferential increase in 
glucose uptake and lactate formation relative to glucose 
oxidation and storage in hyperthyroid state.  This is due 
to increase in both basal and insulin stimulated GLUT1 
and GLUT-4 transporters (13), increased 
responsiveness of glycogenolysis to beta adrenergic 
stimulation (10), increased activity of hexokinase and 5 
phosphofructokinase and decreased sensitivity of 
glycogen synthesis to insulin (14). 
 
Thus the net effect of changes occurring at various 
levels such as gastrointestinal tract, beta cells, 
hepatocytes, adipocytes and skeletal muscles is 
hyperglycemia. 
 
EFFECT OF HYPOTHYROIDISM ON 
GLYCEMIC STATUS 
 
In hypothyroidism, the synthesis and release of insulin 
is decreased (6).  The rate of hepatic glucose output is 
decreased probably due to reduced gluconeogenesis.  A 
post receptor defect has been proposed to explain the 
decrease in insulin stimulated glucose utilization in 
peripheral tissues (10).  The net effect is an increased 
risk of recurrent hypoglycemia in a diabetic individual 
(15). 
 
INTERPLAY OF OTHER HORMONES 
 
In addition to the impact of altered thyroid status per se 
on diabetes, hyperthyroidism is associated with an 
increase and hypothyroidism with a decrease in the 
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secretion of growth hormone and glucocorticoids 
further affecting glucose homeostasis (16, 10). 
 
ASSOCIATION BETWEEN IMMUNE 
MEDIATED (TYPE 1) DIABETES MELLITUS 
AND AUTOIMMUNE THYROID DISEASES 
 
Nearly one third of all newly detected Type 1 diabetes 
mellitus patients have co-existent thyroid autoimmunity 
(TAI)  and  a  high  prevalence  of  thyroid  dysfunction  
which is predominantly hypothyroidism (clinical or 
subclinical) whilst a few have hyperthyroidism. The 
high prevalence of thyroid dysfunction emphasizes the 
importance of routine screening for TAI in all newly 
detected Type 1 diabetes mellitus patients followed by 
annual TSH assay in case TAI is positive (17,18). 
 
Type 1 diabetes may be seen in association with 
hypothyroidism in Down’s syndrome and also in 
patients with congenital rubella (2). Insulin requiring 
diabetes in association with primary hypothyroidism is 
sometimes seen in cases of haemochromatosis (2). 
 
 
Autoimmune polyglandular syndrome type 2 (APS 2) 
which is more common in women and occurs in early 
to middle adulthood is characterized by autosomal 
dominant inheritance and presence of autoimmune 
Addision’s disease, autoimmune thyroid disease and 
immune mediated diabetes. Grave’s disease and 
Hashimotos thyroiditis are also common in ATS2 (18, 
19). 
 
CONCLUSIONS 
 
 
There is inter-dependence between insulin and thyroid 
hormones for normal cellular metabolism so that 
diabetes mellitus and thyroid diseases can mutually 
influence the other disease process (Table 1).  When 
diabetes occurs in euthyroid individuals, it results in 
altered thyroid function tests with no clinical 
dysfunction.  In a patient with preexisting Graves 
Oribitopathy, the risk of visual loss is increased and 
chances of visual recovery is less if co-existing diabetes 
is present. When hyperthyroidism occurs in the setting 
of euglycemia, 2-3% of these individuals may become 
diabetic.  Hyperthyroidism results in deterioration of 
diabetic control while hypothyroidism increases the 
susceptibility to hypoglycemia in diabetic patients 
thereby complicating the diabetic management in these 
individuals. 
 
TABLE 1: DIABETES MELLITUS – THYROID 
DISEASE INTERACTION 
 
Clinical Condition      Effect on Glycemia    Effect onThyroid function  
        /Disease 
 
Diabetes mellitus (DM)-  
In euthyroid individuals  —— ↓ Serum T3  ↑  rT3  
                   ↓ TSH response to TRH 
    Impaired nocturnal TSH peak 
 
Diabetes Mellitus–In         Poor glycemic  ↑ Incidence of dysthyroid  
hyperthyroidism           control     optic neuropathy   
individuals  
  
Hyperthyroidism – In      Glucose intolerance —— 
euglycemic individuals    in 50% cases 
  
       Overt diabetes in 2-3%   
 
Hyperthyroidism- In         Deterioration of   —— 
diabetic individuals         diabetes control   
 
Hypothyroidism- In          Predisposition to ——  
diabetic individuals          recurrent hypoglycemia  
 
In Autoimmune   ——         ↑ Prevalence of  
Type 1 individuals            thyroid disease 
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